Pfizer or Moderna? J&J or AstraZeneca? Before Covid, when was the last time you asked someone what kind of vaccine they got?
The pandemic has revolutionized medicine and biotech — and investors have seen a huge profit as a result. BioNTech has increased more than 22X in just two years. Moderna is up over 28X in the same time period.
Industry insiders now believe the pandemic has sped up the emergence of the biotech sector by as much as a full decade.
We at The Motley Fool have traditionally shied away from biotech stocks because they were unpredictable. But we truly believe this is one of the best new sectors for investing right now.
The Wall Street Journal even said, “Just as the digital revolution drove innovation in the last half of the 20th century, the biotech revolution will drive the first half of the 21st century. Children who study digital coding will be surpassed by those who study the code of life.”
Suffice it to say biotech will be big-money-maker stuff. But many investors believe that it’s too complex to even try to wrangle, which means a lot of these lesser-known biotechs often remain undervalued for a very, very long time…
In fact, the majority that aren’t vaccines have gotten beaten down over the past year, leading to attractive entry points — if you know where to look.
Our team of analysts over at Rule Breakers — the same team that predicted Mercadolibre in 2009 (up 9,818%), Tesla in 2011 (up 17,977%), and Shopify in 2016 (up 7,943%), have id
3 Stocks for the Post-Pandemic Biotech Boom
Go To The SourceRead More